Combination therapy with PCSK9 mAbs in post-MI patients

Combination therapy with PCSK mAbs in postMI patients
10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD - Online CME
  • Overview

    Why should combination therapy, including PCSK9 monoclonal antibodies, be given to ACS patients? Derek Connolly sums up the evidence. With question to test your knowledge.

  • Educational information

    This lecture by Derek Connolly was part of an accredited symposium "Redefining intensive LDL-c management in high CV risk patients The case for combination therapy" held during the virtual ESC Congress 2021.

  • Faculty

    Derek Connolly, MD, PhD is a Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital, Birmingham, UK.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

  • Funding

    Funding for this educational program was provided by unrestricted educational grants received from Amgen, Sanofi, Novartis and Daiichi Sankyo.

    Click here for the meeting report

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free